NEWS
Vaccines at centre of new UK investment for AstraZeneca
Pharmaceutical firm AstraZeneca has outlined plans to invest £650 million in the UK – helping boost the UK’s life sciences sector and grow the economy. This significant investment will enhance public health protection and pandemic preparedness.
AstraZeneca intends to invest
£450 million at its manufacturing site in Speke, Liverpool for the research, development, and manufacture of vaccines; building on the site’s current role in supplying the world-leading childhood vaccination programme. The new facility will
Colorectal cancer to benefit from AI diagnostics
Owkin and University Hospitals Birmingham NHS Foundation Trust (UHB) have announced a new five-year research partnership to use artificial intelligence (AI) to accelerate the screening and diagnosis of a range of diseases, starting with colorectal cancer. Colorectal cancer is the third most common cancer type worldwide, with almost two million cases diagnosed each year. Early detection significantly increases the chances of successful treatment. AI powered diagnostics have the potential to accelerate the screening process, playing a crucial role in facilitating earlier intervention which often leads to better patient outcomes. The first research project in this collaboration aims to evaluate the performance of Owkin’s MSIntuit CRC solution in the United Kingdom across UHB’s cohort of 830 patients with primary colorectal adenocarcinoma. Already CE-marked in the European Union and registered for use by the MHRA, the MSIntuit CRC pre-screening solution assists pathologists in the identification of the Microsatellite Instability (MSI) status of colorectal patients, using a deep learning algorithm on digital histology slides. MSI is an important biomarker for
colorectal cancer; it represents a defect in a cell’s ability to correct mistakes that occur when DNA is replicated. Understanding a patient’s MSI status can support doctors in developing more personalised treatment.
be designed and built to be operationally net zero with power supplied from renewable energy sources. In a further boost for the UK’s resilience
for future pandemics and global health threats, AstraZeneca and the UK Health Security Agency (UKHSA) plan to work in partnership to advance science for developing and evaluating vaccines – using technology from both AstraZeneca’s manufacturing site in Speke and the UKHSA’s Vaccine Development Evaluation Centre (VDEC) at its Porton Down site. AstraZeneca will also expand its
presence at Europe’s largest life sciences cluster in Cambridge with £200 million in investment. The facility will house around 1,000 employees and will be adjacent to its £1.1 billion global R&D Discovery Centre (pictured), which already hosts 2,300 researchers and scientists.
AstraZeneca Chief Executive Officer, Sir Pascal Soriot, said: “AstraZeneca’s planned investment would enhance the UK’s pandemic preparedness and demonstrates our ongoing confidence in UK life sciences.”
Gain time
S-Monovette® Safe. Fast. Sustainable.
Gain with the S-Monovette®
• Reduce time and costs for personnel and material with a minimised haemolysis rate
• Utilise the advantages of a dual system for all vein conditions
• Reduce your CO2 emissions,
waste volume and disposal costs considerably
Blood
collection with the
S-Monovette® & Tempus600®
Gain with Tempus600®
• Shorten the total turnaround time (ToTAT) for clinical specimens
• Save valuable time for your staff with the easy, immediate transport of specimens and relieve existing transport systems
• Take the next step towards laboratory automation
Learn more about the synergy of S-Monovette® & Tempus600®
s-monovette-tempus600.
sarstedt.com
SARSTEDT Ltd. · Optimus Way · Optimus Point · Leicester LE3 8JR · Tel: +44 116 235 9023 · Fax: +44 116 236 6099 ·
info.gb@
sarstedt.com ·
www.sarstedt.com
anz_gain_time_gm_symposium_marketing_120x168_0124.indd 1
WWW.PATHOLOGYINPRACTICE.COM APRIL 2024 10.01.2024 08:44:58 11
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57
